PharmaTell seminar: An active targeting delivery system for BNCT in the treatment of brain glioblastoma Event as iCalendar

(Seminars)

25 August 2014

12 - 1pm

Venue: Seminar Room 503-024 Grafton Campus

Host: School of Pharmacy

Contact info: Phone: +64 9 373 7599 ext 82851

Contact email: enquiries@auckland.ac.nz

Emma Kang
Emma Kang

Brain glioblastoma is a type of malignant brain tumour originates from glial cells. The widely used treatments include surgery, chemotherapy and radiotherapy are still remaining far from satisfactory. Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated by low-energy thermal neutrons and then produce particles with high energy to destroy cells. The successful treatment of brain glioblastoma by BNCT requires the selective delivery of a relatively high concentration of 10B compounds to tumor cells. In this project, a boron agent will be firstly conjugated with a cell penetrating peptide to ensure intracellular delivery. An novel liposomal system will be used for targeting the tumour site as well as to overcome the bllod brain barrier.

Presented by: Emma Kang, PhD candidate, School of Pharmacy


Emma Kang graduated from China Pharmaceutical University in 2013, and had the opportuntiy to come to University of Auckland, New Zealand to undertake her doctoral study with a scholarship provided by the Chinese Scholarship Council.